ArticleOpen forum infectious diseases2017
Association Between Cytomegalovirus Reactivation and Clinical Outcomes in Immunocompetent Critically Ill Patients: A Systematic Review and Meta-Analysis.
Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05898048 (Cytomegalovirus Reactivation in Acute Necrotizing Pancreatitis), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cytomegalovirus Reactivation in Acute Necrotizing Pancreatitis
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does treatment with antiviral medication affect mortality among immunocompetent individuals with cytomegalovirus reactivation? A systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes.The Journal of infectious diseases · 2026Trial
- A review of bloodstream infections-pathogens, pathogenesis, diagnostic strategies, treatment methods-challenges and future aspects.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- The Current Status ofPathogens (Basel, Switzerland) · 2026Article
- Article
- Current practices in the diagnosis and management of HSV and CMV reactivation in German ICUs: an exploratory web-based survey.Frontiers in medicine · 2026Article
- Risk stratification for CMV reactivation in sepsis patients: development of an interpretable machine learning model.BMC infectious diseases · 2025Article
- Cytomegalovirus Reactivation in Critically Ill Patients With Acute Necrotizing Pancreatitis.Open forum infectious diseases · 2025Article
- Herpes Zoster Reactivation Following COVID-19 and the Risk of Renal, Infectious, and Autoimmune Complications: A Global Propensity-Matched Cohort Study.Biomedicines · 2025Article
- Risk Factors for Cytomegalovirus Reactivation and Its Impact on Clinical Outcomes in Immunocompetent Seropositive Patients Admitted to the Intensive Care Unit: A Single-Center Prospective Observational Study.Infectious diseases & clinical microbiology · 2025Article
- Cytomegalovirus reactivation in the lower respiratory tract as an independent risk factor for mortality in critically Ill patients.Critical care (London, England) · 2025Article
- Shared interactions of six neurotropic viruses with 38 human proteins: a computational and literature-based exploration of viral interactions and hijacking of human proteins in neuropsychiatric disorders.Discover mental health · 2025Article
- Cytomegalovirus Blood DNAemia in Patients with Severe SARS-CoV-2 Pneumonia.Infectious disease reports · 2025Article
- Global burden of lower respiratory infections attributable to cytomegalovirus, 1990-2021: a systematic analysis from the MICROBE database.Frontiers in microbiology · 2025Article
- Case Report: Post-surgical Guillain-Barré syndrome as a rare differential diagnosis of flaccid paralysis of the lower extremities in an infant after cardiac surgery.Frontiers in pediatrics · 2025Article
- Drugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Wide Spectrum of Presentations of Cytomegalovirus Infection in Immunocompetent Hosts: An Exhaustive Narrative Review.Pathogens (Basel, Switzerland) · 2024Review
- Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19.Intensive care medicine · 2024Observational
- Cytomegalovirus infection in non-immunocompromised critically ill patients: A management perspective.World journal of virology · 2024Review
- Exploring the relationship between HCMV serostatus and outcomes in COVID-19 sepsis.Frontiers in immunology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of our systematic review was to investigate the association between cytomegalovirus (CMV) reactivation and outcomes in immunocompetent critically ill patients.
methodsWe searched electronic databases and gray literature for original studies and abstracts published between 1990 and October 2016. The review was limited to studies including critically ill immunocompetent patients. Cytomegalovirus reactivation was defined as positive polymerase chain reaction, pp65 antigenemia, or viral culture from blood or bronchoalveolar lavage. Selected patient-centered outcomes included mortality, duration of mechanical ventilation, need for renal replacement therapy (RRT), and nosocomial infections. Health resource utilization outcomes included intensive care unit and hospital lengths of stay.
resultsTwenty-two studies were included. In our primary analysis, CMV reactivation was associated with increased ICU mortality (odds ratio [OR], 2.55; 95% confidence interval [CI], 1.87-3.47), overall mortality (OR, 2.02; 95% CI, 1.60-2.56), duration of mechanical ventilation (mean difference 6.60 days; 95% CI, 3.09-10.12), nosocomial infections (OR, 3.20; 95% CI, 2.05-4.98), need for RRT (OR, 2.37; 95% CI, 1.31-4.31), and ICU length of stay (mean difference 8.18 days; 95% CI, 6.14-10.22). In addition, numerous sensitivity analyses were performed.
conclusionsIn this meta-analysis, CMV reactivation was associated with worse clinical outcomes and greater health resource utilization in critically ill patients. However, it remains unclear whether CMV reactivation plays a causal role or if it is a surrogate for more severe illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.